Previous close | 4.92 |
Open | 5.02 |
Bid | 4.91 x 100 |
Ask | 5.11 x 100 |
Day's range | 4.74 - 5.07 |
52-week range | 4.05 - 9.94 |
Volume | |
Avg. volume | 55,829 |
Market cap | 96.346M |
Beta (5Y monthly) | -0.17 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 24 May 2022 |
1y target est | N/A |
ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2024 Earnings Call Transcript May 9, 2024 ProPhase Labs, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Noella Alexander-Young: Welcome to today’s presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial […]
ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.